Medical artificial intelligence firm Lunit announced on September 8, 2026, that it will present three research abstracts leveraging its AI biomarker platform, Lunit Scope IO, at the 2026 World Conference on Lung Cancer (WCLC 2026). The conference runs from September 12 to 15 at COEX in Seoul, marking its return to South Korea for the first time in 19 years since 2007, according to regional reporting by BioTimes.
The Bottom Line
- Clinical Scope: Lunit is showcasing three distinct studies at WCLC 2026 utilizing its Lunit Scope IO platform to analyze non-small cell lung cancer (NSCLC) tissue slides.
- Subtype Precision: Research indicates that different EGFR variant subtypes exhibit sharply contrasting tumor microenvironments, impacting immune cell infiltration and vascular density.
- Biomarker Development: Additional abstracts examine pathological complete response (pCR) following neoadjuvant chemo-immunotherapy and tissue-based TP53 mutation prediction.
Decoding EGFR Subtypes Through AI Tissue Analysis
The first study presented by Lunit evaluates 494 cases of epidermal growth factor receptor (EGFR) mutation subtypes in non-small cell lung cancer (NSCLC). Using the Lunit Scope IO platform, researchers mapped whole slide images to uncover how the tumor microenvironment shifts across distinct genetic variants. Here is the math: Exon 19 deletion (Ex19del) cases demonstrated elevated densities of tumor-infiltrating lymphocytes. Meanwhile, the L858R subtype showed dominant macrophage infiltration, and Exon 20 insertion (Ex20ins) cases registered the highest density of endothelial cells.
These findings prove that even within the same EGFR mutation category, microenvironments diverge significantly. According to company disclosures, this granular visibility provides a concrete basis for designing targeted therapeutic protocols tailored to specific subtype architectures.
Predicting Treatment Response and Neoadjuvant Outcomes
The second study stems from an international collaboration with a research team led by Dr. Paola Nisticò at the Regina Elena National Cancer Institute in Italy. The team analyzed tissue samples from 32 NSCLC patients who underwent preoperative chemo-immunotherapy to examine correlations with pathological complete response (pCR). Patients reaching pCR displayed active immune cell infiltration alongside prominent tertiary lymphoid structures (TLS). Conversely, patients failing to reach pCR exhibited immune-excluded patterns coupled with active tumor cell proliferation.
By identifying which patients achieve complete remission pathways based on pre-treatment tissue topography, healthcare providers can optimize drug allocation and curtail unnecessary side effects.
Mapping Biomarkers and Financial Implications in AI Diagnostics
| Research Focus | Sample Size / Cohort | Key AI Biomarker Discovery |
|---|---|---|
| EGFR Mutation Subtypes | 494 NSCLC Cases | Ex19del shows high lymphocyte density; L858R shows macrophages; Ex20ins shows endothelial cells. |
| Neoadjuvant Chemo-Immunotherapy | 32 NSCLC Patients (Regina Elena Institute) | pCR linked to active immune infiltration and tertiary lymphoid structures (TLS). |
| TP53 Mutation Prediction | 462 Lung Adenocarcinoma Cases | AI differentiates immune-active TP53 mutated tissue from immune-excluded wild-type tissue. |
The third study tackles lung adenocarcinoma by evaluating 462 patient tissue samples to test the platform’s ability to predict TP53 mutation status without immediate genetic sequencing. Tumors harboring TP53 mutations revealed higher immune activation ratios, whereas wild-type tumors displayed immune exclusion alongside significantly higher stromal fibroblast and endothelial cell densities. As BioTimes reports, the integration of AI diagnostics into oncology workflows is accelerating as hospitals seek cost-effective patient stratification tools.
“We confirmed that clues connecting genetic mutations, the tumor microenvironment, and treatment response can be more easily discovered through AI,” said Lunit CEO Beom-Seok Suh, as reported by BioTimes. “We will continue contributing to precision treatment strategies for cancer patients using Lunit Scope.”
Market Trajectory and Strategic Outlook
As BioTimes market summaries indicate, precision oncology platforms are facing heightened scrutiny from institutional investors demanding clear pathways to clinical reimbursement and scalable commercial adoption. Events like WCLC 2026 serve as critical validation milestones for computational pathology firms navigating global regulatory frameworks and competitive pressures from domestic and international medtech giants.
With three independent abstracts accepted at a premier global venue, Lunit continues to cement its operational footprint across international oncology markets.
